Please wait
Healthcare · Diagnostics & Research · Price, fundamentals, signals, and forward-looking context in one research view.
Healthcare
$27.2B
86.0%
27.70
Current price
$332.66
-0.7% todayUpdated just now
Open
$336.39
Previous close
$335.11
Day range
$329.64 – $337.69
Volume
N/A
27.7x P/E
Awaiting filing
86.0% yield
65/100 measured
Easy to trade
Recent price movement, key market context and the latest company information.
The latest saved price history for LH, with its range and direction at a glance.
Labcorp Holdings Inc. provides laboratory services. It operates in Diagnostics Laboratories and Biopharma Laboratory Services segments. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C, PSA, tests for sexually transmitted diseases, vitamin D testing, microbiology cultures and procedures, and alcohol and other substance abuse tests. It also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases; services related to anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, parentage and donor testing, occupational testing service, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests; and health and wellness services to employers and managed care organizations. In addition, it offers digital pathology solutions, a pathology platforms that support the digitization, centralized review, and sharing of pathology slides; provider and payer digital platforms, an online applications for providers, MCOs, and ACOs; online and mobile applications that enable patients to check offerings, schedule PSC visits, check-in upon PSC arrival, complete documentation, access tests and test results, and manage their accounts; and Generative AI enabled Test Selection, a generative AI enabled tool. It serves clients, third party, medicare/medicaid, patients, pharmaceutical, biotechnology, medical device, diagnostic companies, and CROs. It has a strategic collaboration with the Children's Hospital of Philadelphia to accelerate the discovery, development, and availability of pediatric diagnostics; a strategic alliance with the National Association of Community Health Centers to support current and emerging clinical leaders through the NACHC Leadership Exchange for Chief Medical Officers; and Alliance for Clinical Trials in Oncology to advance national clinical trial for patients diagnosed with colorectal cancer. The company was founded in 1995 and is headquartered in Burlington, North Carolina.
Investors usually follow LH for its dividend profile, valuation signal, sector position, and upcoming company events. The goal here is not just to show numbers, but to explain what they mean in plain English.
Whisone is bullish because fundamentals are solid at 71/100 while there is no strong bear warning from the current data. Whisone has moderate conviction here. The final read is being balanced by the weighted scores for fundamentals, technicals, insider flow, sentiment, event flow, and liquidity.
Whisone v2 splits the read into weighted parts so the score is not just one hidden number.
Fundamentals
Growth, margins, cash flow, and valuation.
Latest net profit
$299M
TTM (2026-06-30)
ROE
11.7%
Return on equity
ROA
5.5%
Return on assets
Debt / equity
0.79
Lower is usually safer.
P/B ratio
3.15
Useful for book value support.
Dividend yield
86.0%
Current income signal.
85/100
Direction
Range-bound
Main supports
Business quality and balance-sheet strength are supporting the outlook.
Recent price behavior and momentum still support follow-through.
Recent price and fundamentals refreshes improve signal reliability.
What can go wrong
Execution risk and market swings can still delay the forecast playing out.
Fair value
$338.30
Analyst view
Buy
Analyst target
$341.50
Forecast refresh
Updated just now
Quality score
70
Growth score
50
These are the external analyst numbers and business outlook figures already synced into the company record.
No external analyst outlook is available for this company yet.
$0.72
2025-02-27
Payment: TBA | Qualification: 2025-02-27 | Yield at declaration: N/A
$0.72
2024-11-26
Payment: TBA | Qualification: 2024-11-26 | Yield at declaration: N/A
A plain-English reading of momentum, trend, volatility, range position, and trading participation.
RSI
N/A
Momentum data is not available yet.
Recent trend
Rising
+7.6% across the latest saved price window.
Volatility
Moderate
Beta is 0.84. Price sensitivity is broadly around the market range.
52-week position
91% of range
Price is trading close to its 52-week high.
Volume confirmation
N/A
Comparable volume data is not available.
Sector spillover signals
high_energy_costs
LH may also move because the HEALTHCARE sector may move with high_energy_costs. Confidence 63%.
PMG-MAN stated the pharmaceutical sector spends a large share of revenue on energy, reducing competitiveness industry-wide.
policy_stability_and_support
LH may also move because the HEALTHCARE sector may benefit from policy_stability_and_support. Confidence 60%.
The sector would benefit from extended Presidential Executive Order, dedicated energy tariffs, and policies encouraging local API production to attract investment and boost local manufacturing.
LH
Labcorp Holdings Inc.
Price: $332.66
P/E: 27.69504
Yield: 86.0%
ABBV
AbbVie Inc.
Price: $256.42
P/E: 72.994286
Yield: 2.7%
ABT
Abbott Laboratories
Price: $110.36
P/E: 36.39806
Yield: 2.3%
ALGN
Align Technology, Inc.
Price: $159.79
P/E: 27.310226
Yield: 0.0%
Industry
Diagnostics & Research
Employees
71000
Exchange
NYQ
Ticker
LH
